, Volume 189, Issue 3, pp 319–329 | Cite as

The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats

  • Kirsten Krebs-Thomson
  • Erbert M. Ruiz
  • Virginia Masten
  • Mahalah Buell
  • Mark A. GeyerEmail author
Original Investigation



The hallucinogen 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is structurally similar to other indoleamine hallucinogens such as LSD. The present study examined the effects of 5-MeO-DMT in rats using the Behavioral Pattern Monitor (BPM), which enables analyses of patterns of locomotor activity and exploration, and the prepulse inhibition of startle (PPI) paradigm.


A series of interaction studies using the serotonin (5-HT)1A antagonist WAY-100635 (1.0 mg/kg), the 5-HT2A antagonist M100907 (1.0 mg/kg), and the 5-HT2C antagonist SER-082 (0.5 mg/kg) were performed to assess the respective contributions of these receptors to the behavioral effects of 5-MeO-DMT (0.01, 0.1, and 1.0 mg/kg) in the BPM and PPI paradigms.


5-MeO-DMT decreased locomotor activity, investigatory behavior, the time spent in the center of the BPM chamber, and disrupted PPI. All of these effects were antagonized by WAY-100635 pretreatment. M100907 pretreatment failed to attenuate any of these effects, while SER-082 pretreatment only antagonized the PPI disruption produced by 5-MeO-DMT.


While the prevailing view was that the activation of 5-HT2 receptors is solely responsible for hallucinogenic drug effects, these results support a role for 5-HT1A receptors in the effects of the indoleamine hallucinogen 5-MeO-DMT on locomotor activity and PPI in rats.


Hallucinogen 5-MeO-DMT M100907 SER-082 WAY-100635 Rat Locomotion Startle Prepulse inhibition PPI 



This work was supported by National Institute on Drug Abuse Award R02 DA02925 and the Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center. M. A. Geyer holds an equity position in San Diego Instruments. These studies were conducted while E. M. Ruiz was conducting an externship from the School of Pharmacy, University of Utrecht, The Netherlands. These experiments comply with the current laws of the United States.


  1. Adams LM, Geyer MA (1982) LSD-induced alterations of locomotor patterns and exploration in rats. Psychopharmacology (Berl) 77:179–185CrossRefGoogle Scholar
  2. Adams LM, Geyer MA (1985a) Effects of DOM and DMT in a proposed animal model of hallucinogenic activity. Prog Neuropsychopharmacol Biol Psychiatry 9:121–132PubMedCrossRefGoogle Scholar
  3. Adams LM, Geyer MA (1985b) A proposed animal model for hallucinogens based on LSD’s effects on patterns of exploration in rats. Behav Neurosci 99:881–900PubMedCrossRefGoogle Scholar
  4. Arnt J, Hyttel J (1989) Facilitation of 8-OH-DPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol 161:45–51PubMedCrossRefGoogle Scholar
  5. Bakshi VP, Swerdlow NR, Braff DL, Geyer MA (1998) Reversal of isolation rearing-induced deficits in prepulse inhibition by seroquel and olanzapine. Biol Psychiatry 43:436–445PubMedCrossRefGoogle Scholar
  6. Berendsen HH, Jenck F, Broekkamp CL (1989) Selective activation of 5HT1A receptors induces lower lip retraction in the rat. Pharmacol Biochem Behav 33:821–827PubMedCrossRefGoogle Scholar
  7. Bervoets K, Millan MJ, Colpaert FC (1990) Agonist action at 5-HT1C receptors facilitates 5-HT1A receptor-mediated spontaneous tail-flicks in the rat. Eur J Pharmacol 191:185–195PubMedCrossRefGoogle Scholar
  8. Boulenguez P, Chaveau J, Segu L, Morel A, Lanoir J, Delaage M (1991) A new 5-hydroxy-indole derivative with preferential affinity for 5-HT1B binding sites. Eur J Pharmacol 194:91–98PubMedCrossRefGoogle Scholar
  9. Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry 47:181–188PubMedGoogle Scholar
  10. Cunningham KA, Appel JB (1987) Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD). Psychopharmacalogy (Berl) 91:67–73CrossRefGoogle Scholar
  11. Darmani NA, Martin BR, Glennon RA (1990) Withdrawal from chronic treatment with (+)-DOI causes super-sensitivity to 5-HT2 receptor-induced head-twitch behaviour in mice. Eur J Pharmacol 186:115–118PubMedCrossRefGoogle Scholar
  12. Dumuis A, Sebben M, Bockaert J (1987) Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture. Mol Pharmacol 33:178–186Google Scholar
  13. Eison AS, Wright RN (1992) 5-HT1A and 5-HT2 receptors mediate discrete behaviors in the Mongolian gerbil. Pharmacol Biochem Behav 43:131–137PubMedCrossRefGoogle Scholar
  14. Gammans RE, Mayol RF, Labudde JA (1986) Metabolism and disposition of buspirone. Am J Med 80:41–51PubMedCrossRefGoogle Scholar
  15. Geyer MA (1990) Approaches to the characterization of drug effects on locomotor activity in rodents. In: Adler MW, Cowan A (eds) Modern methods in pharmacology: testing and evaluation of drugs of abuse. Wiley, New York, pp 81–99Google Scholar
  16. Geyer MA, Krebs KM (1994) Serotonin receptor involvement in an animal model of the acute effects of hallucinogens. In: Lin G, Glennon RA (eds) Hallucinogens: an update (NIDA Research Monograph Series). US Department of Health and Human Services, Rockville, MD, pp 124–156Google Scholar
  17. Geyer MA, Russo PV, Masten VL (1986) Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav 25:277–288PubMedCrossRefGoogle Scholar
  18. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117–154CrossRefGoogle Scholar
  19. Glennon RA (1986) Discriminative stimulus properties of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Pharmacol Biochem Behav 25:135–139PubMedCrossRefGoogle Scholar
  20. Glennon RA, Rosecrans JA (1982) Indolealkylamine and phenalkylamine hallucinogens: a brief overview. Neurosci Biobehav Rev 6:489–497PubMedCrossRefGoogle Scholar
  21. Glennon RA, Rosecrans JA, Young R, Gaines J (1979) Hallucinogens as a discriminative stimuli: generalization of DOM to a 5-methoxy-N,N-dimethyltryptamine stimulus. Life Sci 24:993–998PubMedCrossRefGoogle Scholar
  22. Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980) Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities. Psychopharmacology (Berl) 68:155–158CrossRefGoogle Scholar
  23. Glennon RA, Young R, Jacyno JM, Slusher M, Rosecrans JA (1983) DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines. Eur J Pharmacol 86:453–459PubMedCrossRefGoogle Scholar
  24. Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505–2511PubMedCrossRefGoogle Scholar
  25. Hoffman HS, Ison JR (1980) Reflex modification in the domain of startle: I. Some empirical findings and their implication for how the nervous system processes sensory input. Psychol Rev 87:175–189PubMedCrossRefGoogle Scholar
  26. Holmstedt B, Lindgren JE, Plowman T, Rivier L, Schultes RE, Tovar O (1980) Indole alkaloids in Amazonian Myristicaceae: field and laboratory research. Bot Mus Leaf Harv Univ 28:215–234Google Scholar
  27. Krebs KM, Geyer MA (1994) Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats. Psychopharmacology (Berl) 113:429–437CrossRefGoogle Scholar
  28. Krebs-Thomson K, Geyer MA (1996) The role of 5-HT1A receptors in the locomotor-suppressant effects of LSD: WAY-100635 studies of 8-OH-DPAT, DOI, and LSD. Behav Pharmacol 6:551–559Google Scholar
  29. Krebs-Thomson K, Geyer MA (1998) Evidence for a functional interaction between 5-HT1A and 5-HT2 receptors in rats. Psychopharmacology (Berl) 140:69–74CrossRefGoogle Scholar
  30. Krebs-Thomson K, Paulus MP, Geyer MA (1998) Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacology 18:339–351PubMedCrossRefGoogle Scholar
  31. Lucki I, Frazer A (1982) Prevention of the serotonin syndrome in rats by repeated administration of monoamine oxidase inhibitors but not tricyclic antidepressants. Psychopharmacology (Berl) 77:205–211CrossRefGoogle Scholar
  32. Lucki I, Nobler MS, Frazer A (1984) Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther 228:133–139PubMedGoogle Scholar
  33. Mansbach RS, Geyer MA, Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl) 94:507–514CrossRefGoogle Scholar
  34. Matthews WD, Smith CD (1980) Pharmacological profile of a model for central serotonin receptor activation. Life Sci 26:1397–1403PubMedCrossRefGoogle Scholar
  35. McClue SJ, Brazell C, Stahl SM (1989) Hallucinogenic drugs are partial agonists of the human platelet shape change response: a physiological model of the 5-HT2 receptor. Biol Psychiatry 26:297–302PubMedCrossRefGoogle Scholar
  36. McKenna DJ, Towers GH, Abbott FS (1984) Monoamine oxidase inhibitors in South American hallucinogenic plants part 2: constituents of orally-active myristicaceous hallucinogens. J Ethnopharmacol 12:179–211PubMedCrossRefGoogle Scholar
  37. McKenna DJ, Repke DB, Lo L, Peroutka SJ (1990) Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology 29:193–198PubMedCrossRefGoogle Scholar
  38. Nanry KP, Tilson HA (1989) The role of 5HT1A receptors in the modulation of the acoustic startle reflex in rats. Psychopharmacology (Berl) 97:507–513CrossRefGoogle Scholar
  39. Ouagazzal A, Grottick AJ, Moreau J, Higgins GA (2001) Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology 25:565–575PubMedCrossRefGoogle Scholar
  40. Rigdon GC, Weatherspoon JK (1992) 5-hydroxytryptamine 1A receptor agonists block prepulse inhibition of acoustic startle reflex. J Pharmacol Exp Ther 263:486–493PubMedGoogle Scholar
  41. Schultes RE (1979) Evolution of the identification of the myristicaceous hallucinogens of South America. J Ethnopharmacol 1:211–239PubMedGoogle Scholar
  42. Schultes RE, Raffauf RF (1995) The healing forest: medicinal and toxic plants of the northwest Amazonia. Dioscorides, PortlandGoogle Scholar
  43. Scott PA, Chou JM, Tang H, Frazer A (1994) Differential induction of 5-HT1A-mediated responses in vivo by three chemically dissimilar 5-HT1A agonists. J Pharmacol Exp Ther 270:198–208PubMedGoogle Scholar
  44. Shulgin A, Shulgin A (1997) TiHKAL: the continuation. Transform, Berkeley, CAGoogle Scholar
  45. Sipes TE, Geyer MA (1995a) 8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100,135 and localization of site of action. Psychopharmacology (Berl) 117:41–48CrossRefGoogle Scholar
  46. Sipes TE, Geyer MA (1995b) DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT2A and not by 5-HT2C receptors. Behav Pharmacol 6:839–842PubMedGoogle Scholar
  47. Sloviter RS, Drust EG, Connor JD (1978) Specificity of a rat behavioral model for serotonin receptor activation. J Pharmacol Exp Ther 206:339–347PubMedGoogle Scholar
  48. Smith LM, Peroutka SJ (1986) Differential effects of 5-hydroxytryptamine1A selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem Behav 24:1513–1519PubMedCrossRefGoogle Scholar
  49. Spencer DG, Glaser T, Traber J (1987) Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine. Psychopharmacology (Berl) 93:158–166Google Scholar
  50. Thomson KK (1996) Multiple serotonin receptor influences in the behavioral effects of hallucinogens in rats: the role of 5-HT1A and 5-HT2 receptors Psychology. UCSD, La JollaGoogle Scholar
  51. Titeler M, Lyon RA, Glennon RA (1988) Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl) 94:213–216Google Scholar
  52. Tricklebank MD, Forler C, Middlemiss DN, Fozard JR (1985) Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat. Eur J Pharmacol 117:15–24PubMedCrossRefGoogle Scholar
  53. Winter JC, Filipink RA, Timineri D, Helsley SE, Rabin RA (2000) The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol Biochem Behav 65:75–82PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Kirsten Krebs-Thomson
    • 1
  • Erbert M. Ruiz
    • 1
  • Virginia Masten
    • 1
  • Mahalah Buell
    • 1
  • Mark A. Geyer
    • 1
    Email author
  1. 1.Department of PsychiatryUniversity of California, San DiegoLa JollaUSA

Personalised recommendations